Literature DB >> 10547701

Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.

E A Johnson1.   

Abstract

Toxins are increasingly being used as valuable tools for analysis of cellular physiology, and some are used medicinally for treatment of human diseases. In particular, botulinum toxin, the most poisonous biological substance known, is used for treatment of a myriad of human neuromuscular disorders characterized by involuntary muscle contractions. Since approval of type-A botulinum toxin by the US Food and Drug Administration in December 1989 for three disorders (strabismus, blepharospasm, and hemifacial spasm), the number of indications being treated has increased greatly to include numerous focal dystonias, spasticity, tremors, cosmetic applications, migraine and tension headaches, and other maladies. Many of these diseases were previously refractory to pharmacological and surgical treatments. The remarkable therapeutic utility of botulinum toxin lies in its ability to specifically and potently inhibit involuntary muscle activity for an extended duration. The clostridia produce more protein toxins than any other bacterial genus and are a rich reservoir of toxins for research and medicinal uses. Research is underway to use clostridial toxins or toxin domains for drug delivery, prevention of food poisoning, and the treatment of cancer and other diseases. The remarkable success of botulinum toxin as a therapeutic agent has created a new field of investigation in microbiology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547701     DOI: 10.1146/annurev.micro.53.1.551

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  37 in total

1.  A molecular basis underlying differences in the toxicity of botulinum serotypes A and E.

Authors:  Mark Bajohrs; Colin Rickman; Thomas Binz; Bazbek Davletov
Journal:  EMBO Rep       Date:  2004-11       Impact factor: 8.807

2.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

3.  Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.

Authors:  Sabine Pellett; William H Tepp; Larry H Stanker; Philip A Band; Eric A Johnson; Konstantin Ichtchenko
Journal:  Biochem Biophys Res Commun       Date:  2011-02-01       Impact factor: 3.575

4.  Recombinant holotoxoid vaccine against botulism.

Authors:  Christina L Pier; William H Tepp; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri; Michael R Baldwin
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

5.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

Review 6.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

7.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

8.  Purification and characterization of a novel subtype a3 botulinum neurotoxin.

Authors:  William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Appl Environ Microbiol       Date:  2012-02-24       Impact factor: 4.792

9.  Differentiation of the gene clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab, and A(B) strains.

Authors:  Giovanna Franciosa; Francesca Floridi; Antonella Maugliani; Paolo Aureli
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

10.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Authors:  Min Dong; Huisheng Liu; William H Tepp; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.